Topical Therapy for Atopic Dermatitis What is New and the New Paradigm

被引：2
作者：
Buethe, Maria Gnarra [1 ,2 ,5 ]
Kellogg, Caitlyn [1 ,2 ,6 ]
Seo, Young Joon [1 ,2 ,3 ,7 ]
Vuong, Carrie [1 ,2 ,8 ]
Eichenfield, Lawrence F. [1 ,2 ,4 ]
机构：
[1] Rady Childrens Hosp San Diego, Div Pediat & Adolescent Dermatol, San Diego, CA USA
[2] Univ Calif San Diego, Sch Med, Dept Dermatol, La Jolla, CA USA
[3] Chungnam Natl Univ, Coll Med, Dept Dermatol, Daejeon, South Korea
[4] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA USA
[5] 2683 Via Valle,Suite G 210, Del Mar, CA 92014 USA
[6] 6501 Forum St, San Diego, CA 92111 USA
[7] 11232 Vista Sorrento Pkwy,M210, San Diego, CA 92130 USA
[8] 3071 Sunset Canyon Dr, San Diego, CA 92117 USA
来源：
DERMATOLOGIC CLINICS | 2024年 / 42卷 / 04期
关键词：
Atopic dermatitis; Topicals; Ruxolitinib; Roflumilast; Crisaborole; Tapinarof; ARYL-HYDROCARBON RECEPTOR; TAPINAROF; PSORIASIS; CREAM;
D O I：
10.1016/j.det.2024.05.001
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：569 / 575
页数：7
相关论文
共 41 条
  • [1] [Anonymous], 2023, Prescribing Information for Opzelura (Ruxolitinib) Cream 1.5%
  • [2] [Anonymous], 2023, A Study to Evaluate Long-Term Maintenance Treat- ment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to- Moderate Atopic Dermatitis
  • [3] [Anonymous], 2024, Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA (Tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
  • [4] Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137
  • [5] Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration
    Baurecht, Hansjorg
    Ruhlemann, Malte C.
    Rodriguez, Elke
    Thielking, Frederieke
    Harder, Inken
    Erkens, Anna-Sophie
    Stolzl, Dora
    Ellinghaus, Eva
    Hotze, Melanie
    Lieb, Wolfgang
    Wang, Sheng
    Heinsen-Groth, Femke-Anouska
    Franke, Andre
    Weidinger, Stephan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (05) : 1668 - +
  • [6] A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
    Bissonnette, Robert
    Call, Robert S.
    Raoof, Tooraj
    Zhu, Zhaoyin
    Yeleswaram, Swamy
    Gong, Xiaohua
    Lee, Mark
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 355 - 364
  • [7] Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent
    Bissonnette, Robert
    Gold, Linda Stein
    Rubenstein, David S.
    Tallman, Anna M.
    Armstrong, April
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (04) : 1059 - 1067
  • [8] Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bhatia, Neal
    DuBois, Janet
    Forman, Seth B.
    Gooderham, Melinda
    Green, Lawrence
    Guenthner, Scott T.
    Hebert, Adelaide A.
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Kato, Saori
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (05) : 986 - 993
  • [9] JAK inhibitors in the treatment of atopic dermatitis
    Chovatiya, Raj
    Paller, Amy S.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (04) : 927 - 940
  • [10] Clinicaltrials.gov, 2023, Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (IntegumentPED)
12345